Rami Rahal Email & Phone Number

Cambridge, MA, US

Boston, Massachusetts, US

Boston, Massachusetts, US

Leveraging the power of chemoproteomics and covalent small molecules to selectively drug 'intractable' cancer drivers. Team building.

Lexington, MA, US

Small molecule drug discovery for in vivo validated IO targets, immunogenomics, multi-dimensional profiling of the tumor immune microenvironment, team building.

Cambridge, Massachusetts, US

• Project team leader of an immuno-oncology program in collaboration with a large pharmaceutical partner
• Formulated and communicated the program’s strategy to the joint research committee
• Facilitated project team meetings, cross-functional communication and decision making
• Contributed to the design of experimental strategies to validate and understand the mechanism of action for a novel target
• Guided the development of novel human and mouse immune assay systems to drive SAR and lead small-molecule selection
• Integrated cellular, molecular, and genomic approaches to interrogate target biology and inform indication selection and patient identification strategiesBiology lead for BLU-667, the first highly potent and selective.

Cambridge, Massachusetts, US

Identification of new therapies for genetically defined cancers: - Conceived and developed a novel target identification strategy to reveal kinase targets Lead an experimental strategy to identify next-generation inhibitors of a kinase genetically deregulated in multiple cancer subtypes: - Prospectively identified mutations that promote resistance to.

Basel, Baselstadt, CH

• Used next-generation sequencing (RNA-seq) and pharmacological profiling to identify novel therapeutic targets for mantle cell lymphoma (MCL)
• Identified a pattern of mutually exclusive activation of the classical and alternative NFκB pathways in MCL lines that were sensitive or insensitive to BTK/PKC inhibition, respectively
• Used RNA-seq to characterize genetic features associated with compound sensitivity and identified activating lesions in the alternative NFκB pathway in MCL lines insensitive to BTK/PKC inhibitors
• Discovered similar NFκB pathway-activating mutations in in approximately 10% of MCL patients
• Identified potential biomarkers of deregulated classical or alternative NFκB pathway signaling to facilitate patient stratification for clinical trials with BTK/PKC or NIK inhibitors, respectively

Boston, MA, US

Characterized molecular pathways that respond to mitochondrial dysfunction using a combination of transcriptional profiling, metabolomics, and analysis of signal transduction cascades.

Cambridge, MA, US

Investigated the molecular mechanisms by which mitotic cyclin-dependent kinases coordinate genome segregation during cell division.

Phd, Genetics

Bachelor Of Science, Biochemistry